Functional Concept
BiomX’s phage therapy shows promise in Phase II diabetic foot infections study
BX211, Phage Therapy, DFO
Back to the drawing board for Vertex’s ‘cells plus device’ diabetes programme
Vertex Pharmaceuticals, VX-264, type 1 diabetes, cell therapy, implantable device, clinical trial failure, zimislecel, insulin production
Bluebird bio receives rival M&A bid worth 50% higher than Carlyle-SK offer
Ayrmid, Family Turdidae (organism), Twice a day, gene therapy, Carlyle, High, Bluebird Bio, Capital
Vertexs second-generation diabetes cell therapy fails early-stage study
Failed, VX-264, Allogeneic Human Stem Cell-derived Pancreatic Islet Cells VX-880
Lilly’s Lepodisiran Shows Durable Lipoprotein(a) Reduction in Phase 2 Trial
lepodisiran, lipoprotein(a), Lp(a), cardiovascular disease, RNA interference, long-acting therapy
FDA Shakeup: Peter Marks’ Resignation Rattles Biotech Industry
Peter Marks, FDA resignation, biotech stocks, regulatory uncertainty, drug approvals
Beyond Black Box: How Data-Driven AI Is Transforming RNA Medicine Development
Aortic Valve Insufficiency, development aspects, RNA medicine, black box, Data-Driven AI, Transforming RNA Medicine Development, datasets, Drug Design, Clinical Trials
CHMP recommends seven label expansions and one new approval, rejects Lilly Alzheimer’s drug
CHMP, Labels (device), expansions, Approved
Novo inks second obesity deal of the week, with Lexicon oral drug partnership worth up to $1B
Obesity, LX9851, lexicon, Mechanism (attribute)
BioNTech shows off lung cancer survival data behind phase 3 push for red-hot bispecific
BNT327, BioNTech, month, BioNTech ‘s, Small cell carcinoma of lung, Pharmacotherapy